Skip to main content
. Author manuscript; available in PMC: 2019 Dec 3.
Published in final edited form as: Bioconjug Chem. 2017 Jul 6;28(7):1993–2000. doi: 10.1021/acs.bioconjchem.7b00313

Figure 4.

Figure 4.

Dextran-CpG inhibits tumor growth when combined with whole tumor cell vaccine. C57BL/6 mice (n = 8/group) were inoculated with 3 × 105 TC-1 tumor cells s.c. in the flank and treated with PBS or immunized with soluble or Dextran-CpG + TC-1 tumor cells on days 5 and day 12 (1.24 nmol CpG, 1 × 106 freeze−thawed TC-1 cells). Tumor growth (a) and Kaplan−Meier survival (b) of mice were monitored over time. (c), on day 11 post tumor inoculation, mice were bled and antigen-specific CD8+ T cells were analyzed by H-2Db restricted E7 peptide (an immune dominant epitope) tetramer staining. Data show the mean values ± SEM: *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; n.s., not significant.